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Abstract
Background: In December 2001, a fatal case of pneumococcal meningitis in a Marine Corps
recruit was identified. As pneumococcal vaccine usage in recruit populations is being considered,
an investigation was initiated into the causative serotype.
Case presentation: Traditional and molecular methods were utilized to determine the serotype
of the infecting pneumococcus. The pneumococcal isolate was identified as serotype 38 (PS38), a
serotype not covered by current vaccine formulations. The global significance of this serotype was
explored in the medical literature, and found to be a rare but recognized cause of carriage and
invasive disease.
Conclusion: The potential of PS38 to cause severe disease is documented in this report. Current
literature does not support the hypothesis that this serotype is increasing in incidence. However,
as we monitor the changing epidemiology of pneumococcal illness in the US in this conjugate era,
PS38 might find a more prominent and concerning niche as a replacement serotype.
Background
In December 2001, the Department of Defense Center for
Deployment Health Research at the Naval Health
Research Center (NHRC) was consulted regarding a case
of fatal meningitis caused by Streptococcus pneumoniae
(pneumococcus) in a Marine Corps recruit.
The pneumococcus is a common cause of fatal bacterial
meningitis in the US [1]. A 23-valent polysaccharide vac-
cine and a 7-valent conjugate pneumococcal vaccine are
available and potentially effective in protecting against
serotype-specific invasive infections. For this reason, it is
important to determine whether clinically significant
pneumococcal infections are vaccine-covered serotypes,
particularly in settings like military training camps where
epidemic spread can occur.
Case presentation
On December 22, 2001, an 18-year-old male in his eighth
week of Marine Corps basic training presented to the field
medical station with headache and an episode of vomit-
ing after physical training.
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His neurological symptoms progressed over the next sev-
eral hours until he became disoriented and unresponsive.
He was evaluated in the local hospital emergency depart-
ment where a fever of 39.1C (102.5F) and disorientation
to person, place, and time were observed. Lumbar punc-
ture performed during medical evaluation revealed an
opening pressure greater than 500 mm; cerebrospinal
fluid (CSF) was milky white, with a glucose concentration
of 3 mg/dl and total protein of 269 mg/dl. White count in
the CSF was 4444 with 91% segmented neutrophils, and
microscopic evaluation of the CSF revealed Gram-positive
diplococci. A presumptive diagnosis of pneumococcal
meningitis was made; intravenous ceftriaxone, ampicillin,
and vancomycin were initiated. Despite these measures,
the patient's condition remained unimproved. He was
transferred to the intensive care unit of a tertiary care hos-
pital on ventilator support. Intravenous dexamethasone
was initiated; antibiotics and supportive care were contin-
ued. He died approximately 30 hours after his initial pres-
entation to the field medical station.
The patient had no previous history of meningitis, neuro-
logic abnormalities or other medical problems. Prior to
onset of his illness, there was no history of head trauma,
and he was taking no medications. He received a menin-
gococcal vaccination (Menomune A/C/Y/W135, Aventis
Pasteur) on October 31, 2001. He had no history of
receiving pneumococcal vaccination.
Laboratory evaluation
Blood and CSF cultures were positive for Streptococcus
pneumoniae, sensitive to all antibiotics tested. Streptococ-
cal culture of the throat was negative.
A pneumococcal isolate from the blood was sent to the
Respiratory Disease Laboratory at NHRC for additional
evaluation. Serotyping was performed using a modified
version of the latex agglutination typing method [2]. Sam-
ples were tested against antisera for vaccine-covered sero-
types (Statens Serum Institut, Denmark) and results
confirmed using the classic Quellung reaction and multi-
locus sequence typing (MLST) technique.
For MLST, chromosomal DNA was extracted using spin
DNA extraction columns (Qiagen, Valencia, CA). A subse-
quent PCR reaction was carried out in 100-µl volumes,
using primer pairs developed by Enright and Spratt [3].
Each of the primer pairs amplify an internal fragment of 7
housekeeping genes: aroE, gdh, gki, recP, spi, xpt, and ddl.
Amplified DNA fragments were purified using QIAquick
purification columns (Qiagen, Valencia, CA) and directly
sequenced in each direction on an automated sequencer
with Big Dye terminator chemistry (Applied Biosystems,
Foster City, CA). Allelic matches at each loci were deter-
mined through a search engine at the pneumococcal
MLST Web site http://www.mlst.net.
Using the classic serotyping methods outlined, the isolate
did not react with any of the 23-valent vaccine-specific
typing antisera. Molecular investigation utilizing MLST
demonstrated an allelic profile that matched sequence
type 393. Using the MLST database, this sequence type
matched a likely pneumococcal serotype 38 (PS38). The
latex agglutination was repeated using antisera against
this serotype, and results were confirmatory.
PS38 is not covered by the current 23-valent polysaccha-
ride or the 7-valent conjugate pneumococcal vaccine for-
mulations, which include pneumococcal serotypes that
are considered the most common causes of invasive and
antibiotic-resistant infections in the US. Given the fatal
outcome in this case and the importance of vaccine for-
mulations being appropriately targeted, the medical liter-
ature was explored to evaluate pneumococcal disease
caused by PS38 in the US and outside the US. Particular
emphasis was placed on temporal trends and documented
cases of meningitis caused by this serotype.
PS38 in the US
Within the US, relatively few cases of PS38 disease have
been reported. A few reported PS38 carriage isolates were
found (3/235, 1.3%) from Alabama 1975 to 1978, but no
cases of PS38 were among the 105 invasive isolates tested
[4]. From 1985 to 1989 in Alabama, no PS38 was noted
among 303 cases of meningitis or bacteremia, and only 2
cases were found among 228 cases of otitis media [5].
Black and colleagues reported two cases of invasive PS38
disease in children attending clinics in northern Califor-
nia from October 1995 to August 1998 [6]. A comprehen-
sive analysis of pneumococcal isolates recovered from
patients with invasive disease in the US in 1999 was per-
formed by Gertz and colleagues. Among 1,168 isolates
examined, only 5 were identified as PS38 (0.4%) [7].
More recently, three of 185 (1.6%) invasive isolates, and
only 8/1379 (0.6%) carriage isolates were found to be
PS38 among isolates from Alaska, 1998 to 2002 [8].
Given the invasive:carriage ratio of this and other ana-
lyzed studies, this report concluded that although the
invasive  potential  of PS38 was similar to other vaccine
serotypes, the carriage was so low that the significance of
serious infections caused by PS38 was minimal at that
time. Although not specified, meningitis was likely
among these few documented invasive illnesses caused by
PS38 within the US.
In a large review of the Active Bacterial Core Surveillance
(ABCs) performed by Robinson and colleagues from 1995
to 1998, serotype 38 was not mentioned among the top
14 serotypes [9]. Likewise, numerous other studies failedBMC Infectious Diseases 2005, 5:38 http://www.biomedcentral.com/1471-2334/5/38
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to reveal PS38 among the reported contributing serotypes
[1,10].
PS38 outside the US
Cases of invasive PS38 disease have been reported in Aus-
tralia, Spain, England, and Canada in recent years [11-16].
One Australian study identified 7 (12.4%) cases of inva-
sive PS38 disease in non-indigenous adolescents, making
PS38 the second most common non-vaccine covered sero-
type identified in this population [11]. Of particular inter-
est is the study of pneumococcal isolates causing local and
invasive disease in Spain from January 1997 to June 2001.
Unlike the previous studies, a strain of PS38 was identi-
fied that was resistant to penicillin (MIC > 0.06 mg/L)
[14].
In addition to causing invasive pneumococcal infections,
PS38 has been found in isolates from children with acute
otitis media in the Czech Republic [17] and from
nasopharyngeal swabs in a study of pneumococcal car-
riage in Canadian children attending daycare from 1995
to 1996 [18]. In the study of pneumococcal carriage, PS38
ranked the 14th most common serotype, with 8 out of
589 (1.36%) isolates positive for PS38.
In contrast to these small studies with recognized PS38
disease or carriage, numerous other comprehensive
reports from outside the US failed to demonstrate a bur-
den. A review of over 70 global data sets performed by
Hausdorff and colleagues failed to reveal PS38 among the
top 25 serotypes identified among children; however,
PS38 did rank #23 out of the top 24 isolates identified
from adults [19]. In a paired report, Hausdorff did not
assign significance to PS38 as he evaluated the disease
manifestations of the top 16 global pneumococcal sero-
types [20]. Likewise, in subsequent studies, PS38 was not
mentioned among isolates of importance for otitis media
or for invasive disease in the literature outside the US
[8,21,22]. More recently, among invasive isolates consid-
ered: 150 from studies in Oxford, England, 1995–2001
[23]; 92 from Iceland, 1992–2001 [8]; 69 from Toronto,
1995 [24]; 112 from Kenya, 1992–1996 [25], and 56 from
Papau New Guinea, 1981–1987 [26], PS38 was again not
among the serotypes identified.
Among reports of studies outside the US that specifically
address meningitis cases caused by PS38, Table 1 summa-
rizes reports from Africa, Asia, Europe, and South America
from the late 1970s to the mid-1990s. The prevalence of
PS38-associated meningitis ranged from 0.2% in South
Africa to 5.6% in Southern India. Of the cases with
reported antibiotic sensitivities, all were penicillin-suscep-
tible [27,28]. In four of the five reports, PS38 meningitis
was among the 23 most common serotypes reported [28-
31].
Of the PS38 disease reported outside the US, invasive
pneumococcal disease was not uncommon. Additionally,
even though most PS38 isolates tested were pan-sensitive
to broad-spectrum antibiotics, antibiotics can be ineffec-
tive in a rapidly fulminating infection. This suggests con-
sidering primary measures such as vaccination for PS38
disease prevention. In some countries, PS38 was impli-
cated in enough cases of invasive disease to be considered
for inclusion into a 14- or 23-valent vaccine formulated
for that region [28-31]. Although PS38 seems to be a spo-
radic cause of pneumococcal disease worldwide, temporal
trends of increasing incidence were not appreciated.
Conclusion
Streptococcus pneumoniae serotype 38 has been an uncom-
mon cause of pneumococcal disease in the US and thus, is
not included in commercial vaccine formulations. The
significance of this serotype might be more important
outside the US. Although the invasive potential of PS38 is
documented, cases are rare. Prior to this report, a defini-
tive meningitis death in the US caused by PS38 was not
found in our review of the literature; nevertheless, there is
little current evidence that PS38 is gaining in incidence or
importance.
As we monitor the changing epidemiology of pneumococ-
cal illness in the US in this conjugate era, PS38, with its
documented invasive potential, might find a more prom-
Table 1: Epidemiology of PS38 Meningitis Cases Outside the US. Studies outside the US of Streptococcus pneumoniae serotype 38 
(PS38) isolated from the cerebrospinal fluid (CSF) of individuals being considered for the clinical diagnosis of meningitis.
Location Time Period No. of Cases Prevalence of PS38 Antibiotic Susceptibility Patient Age Group
Cairo, Egypt [29] Late 1970s 3 2.3% NP Infants, Children, adults
South Africa [27] 1979–1986 2 0.2% Pan-sensitive NP
São Paulo, Brazil [30] 1977–1988 13 1.3% NP Children, adults, elderly
Southern India [31] 1992–1993 1 5.6% NP Children
Netherlands [28] 1994 3 2.0% Penicillin-susceptible NP
NP = Not providedBMC Infectious Diseases 2005, 5:38 http://www.biomedcentral.com/1471-2334/5/38
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inent and concerning niche as a replacement serotype.
Continued laboratory-based surveillance with a focus on
emerging strains and the changing epidemiology is critical
for optimal development of future prevention efforts in
these dynamic times.
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